aibioAcumen Pharmaceuticals agrees to $35.75 million private placement at $3.30 per share
Tickers ABOS
Acumen Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional and accredited investors. RA Capital Management, an existing investor, led the deal, and the release names no placement agent.
Key facts
- Company
- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS)
- News type
- Financings
- Primary source
- Acumen Pharmaceuticals, Inc. 8-K (2026-03-16)
The terms
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) announced on March 16, 2026 that it had entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. The company expects gross proceeds of approximately $35.75 million, before offering expenses. The release does not give the number of shares, and it does not mention warrants.
The placement was led by existing investor RA Capital Management, with participation from other investors including ADAR1 Capital Management, Sands Capital and what the company calls a large investment management firm, which it does not name. It is expected to close on or about March 16, 2026, subject to customary closing conditions. The shares are not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption. Acumen agreed to file a registration statement for the resale of the shares no later than two business days after it files its annual report on Form 10-K for the fiscal year ended December 31, 2025.
Banks and advisors
The release names no placement agent, financial advisor, legal counsel or fee. The release does not say whether any bank was engaged.
What the money is for
Acumen says proceeds are expected to primarily support its Enhanced Brain Delivery program, or EBD, including preclinical development work to support nomination of a lead clinical candidate molecule, and working capital and other general corporate purposes. The company targets submission of an investigational new drug application for a lead clinical candidate in mid-2027, so the money funds work that is still preclinical.
Chief Executive Officer Daniel O'Connell said the financing "strongly validates our portfolio and our Enhanced Brain Delivery strategy." That is the company's framing of investor demand, not independent evidence about the science.
The preclinical data
On the same day Acumen announced preclinical results from the EBD program, run with JCR Pharmaceuticals' blood-brain barrier technology, J-Brain Cargo. The company says its development candidates reached 14-40x higher brain levels in non-human primates than native antibodies at 24 hours, that hematology data in the primates indicate a low potential for anemia with no adverse effects observed, and that stability supports subcutaneous dosing with low-volume devices. The release's headline figure of up to 40-fold is the top of that range. These are animal results, and the release gives no human data for the EBD candidates. Jim Doherty, President and Chief Development Officer, said Acumen's is the only EBD program in the anti-amyloid space that pairs an amyloid-beta oligomer-targeting antibody with a validated transferrin-receptor-targeting antibody technology.
The EBD program is part of a collaboration with JCR announced in July 2025. The release says J-Brain Cargo delivers drugs to tissues including the central nervous system through receptor-mediated transcytosis, and that the first drug built on it, IZCARGO (pabinafusp alfa), is approved in Japan for a lysosomal storage disorder.
The lead drug
Acumen's lead candidate, sabirnetug (ACU193), is in the ongoing Phase 2 trial ALTITUDE-AD in early symptomatic Alzheimer's disease patients, which the company says follows positive Phase 1 results in INTERCEPT-AD. It is also investigating a subcutaneous formulation using Halozyme's ENHANZE technology. The company's 2024 annual report describes sabirnetug as a monoclonal antibody designed to bind soluble amyloid-beta oligomers, and says it came from more than a decade of work that included a drug discovery partnership with Merck & Co., Inc. from 2003 to 2011. The company says that its scientific founders pioneered research on these oligomers.